GlassScriptPhysician profile
Emily Bush
NPI 1053795757
$2,365.38
in general payments reported to CMS, 2019-2025
21 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.45 · 2024: $845 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,205 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.94 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $373.12 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $357.44 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $245.47 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $201.60 | 2024-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $199.00 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $187.47 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $145.83 | 2024 | Lybalvi, Aristada, Vivitrol |
| Janssen Pharmaceuticals, INC | $84.42 | 2024-2025 | Spravato |
| Collegium Pharmaceutical, INC. | $82.81 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $82.15 | 2024-2025 | Loreev Xr, Teriparatide |
| Corium, LLC | $71.54 | 2024-2025 | Azstarys |
| Sanofi-Aventis U.S. LLC | $62.45 | 2021 | |
| Neos Therapeutics, LP | $60.20 | 2024-2025 | Adzenys Xr-Odt |
| Biogen, INC. | $50.51 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $29.59 | 2025 | Qelbree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $28.82 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $22.30 | 2025 | Sunosi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.41 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $21.25 | 2024 | Cobenfy |
| Tris Pharma INC | $19.84 | 2024 | Dyanavel Xr |
| Lilly USA, LLC | $18.16 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.